NV40 Stock Chart & Stats
€0.29
€0.00(0.00%)
At close: 4:00 PM EDT
€0.29
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.81M
Enterprise Value€5.85
Total Cash (Recent Filing)€8.35M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 13, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.13Price Target Upside3391.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase IIb EfficacyHigh and durable response rates from the 12‑month CLOVER WaM (N=55) materially reduce clinical risk for a pivotal program. Durable responses and benefit in BTKi‑exposed/refractory subgroups strengthen the case for a targeted label, improving long‑term commercial and clinical viability if confirmed in Phase III.
Clear Regulatory Path & Breakthrough StatusBreakthrough designation plus a defined accelerated‑approval and Phase III strategy with PFS as primary endpoint creates a structural pathway to earlier market access. This reduces regulatory uncertainty and can shorten time to approval, improving the company's strategic runway and partnerability over the medium term.
Material Committed Financing To Fund Late‑stage WorkAn oversubscribed financing that provides substantial capital upfront materially strengthens near‑term liquidity to initiate and sustain Phase III and CLR125 activities. Committed resources reduce immediate refinancing pressure and enable continuity of pivotal development and regulatory engagement into critical milestones.
Bears Say
Pre-revenue With Sustained Cash BurnThe company remains pre‑revenue and cash‑consumptive, with sizable TTM losses and negative operating cash flow. Structurally, this necessitates repeated external funding, increases dilution risk, and leaves operations contingent on clinical progress or partnerships rather than internal cash generation over the next several quarters.
Milestone‑ And Market‑contingent FundingA large portion of planned capital is contingent on clinical, regulatory and market conditions (warrant milestones and stock trading thresholds). This conditional funding structure creates execution and market‑performance risk that could leave the company undercapitalized if milestones or market conditions are not met in a timely way.
Weakened Balance Sheet & Dilution HistoryMaterial erosion of equity over recent years and prior periods of negative equity indicate a thin capital cushion. That weakens downside protection, increases the likelihood management must issue further equity for operations, and constrains strategic flexibility if clinical or regulatory setbacks occur during pivotal development.
Cellectar Biosciences News
NV40 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was €0.28 and its highest was €0.29 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is €17.81M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on May 14, 2026. The company reported -€1.151 earnings per share for the quarter, beating the consensus estimate of -€1.631 by €0.48.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.45.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -€1.151 in its last earnings report, beating expectations of -€1.631. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in DE:NV40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
NV40 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major clinical progress for iopofosine (robust Phase IIb 12‑month data with high ORR, durable responses, and regulatory strategy toward accelerated approval) and an oversubscribed financing structure intended to fund late‑stage development. Operational progress on CLR125 and cost discipline were also highlighted. Key risks include a low pre‑financing cash balance, reliance on milestone‑contingent funding with market‑performance conditions, continued net losses, and tight timelines for Phase III initiation and regulatory milestones. On balance, the positive clinical data and financing momentum significantly outweigh the contingent funding and timing risks.View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
€10.13
▲(3391.47% Upside)